Tumor News and Research

RSS

Juvenile Arthritis patients may have difficulties achieving educational success

As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood.

31 May 2012

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

31 May 2012

UCLA research projects aim to improve lives of children with serious illnesses

New hope for deadly pediatric brain tumors; opening the door to improved diagnosis and treatment of epilepsy in children; and advanced genetic testing to better understand the causes of autism and cancer in kids. These research projects are currently underway at Mattel Children's Hospital UCLA under the umbrella of the UCLA Children's Discovery and Innovation Institute (CDI), and aim to dramatically improve the lives of children with serious illnesses.

31 May 2012

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.

31 May 2012

Foundation Medicine introduces first pan-cancer genomic profile

Foundation Medicine announced today the commercial launch of FoundationOne, the first pan-cancer, fully informative genomic profile designed to help oncologists expand their patients' treatment options.

31 May 2012

GE to provide attendees with overview of new oncology solutions at ASCO annual meeting

GE Healthcare, is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today.

31 May 2012

Exelixis commences cabozantinib phase 3 pivotal trial in mCRPC

Exelixis, Inc. today announced the initiation of COMET-1, a phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer.

31 May 2012

Gender link discovered for colorectal cancer

Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.

30 May 2012

Pituitary tumors may lead to glaucomatous changes

Certain tumors of the pituitary gland are associated with glaucomatous abnormalities of the optic nerve head, such as enlarged beta zone, an international research team reports.

30 May 2012

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.

30 May 2012

Nature Genetics publishes results from whole genome-wide study of recurrent HBV integration in HCC

The Asian Cancer Research Group (ACRG)—an independent, not-for-profit company established by Eli Lilly and Company, Merck (known as MSD outside the United States and Canada) and Pfizer Inc.—in collaboration with BGI—the world's largest genomics organization—today announced the publication of results from a whole genome-wide study of recurrent hepatitis B virus (HBV) integration in hepatocellular carcinoma (HCC) in Nature Genetics.

30 May 2012

ASCs promising source of cells for use in plastic surgery and regenerative medicine

Adipose stem cells (ASCs)—stem cells derived from fat—are a promising source of cells for use in plastic surgery and regenerative medicine, according to a special review in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

30 May 2012

Marshall Edwards initiates ME-344 Phase I trial in solid tumors

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors.

30 May 2012

Scientists develop synthetic peptide that overcomes cancer cells’ survival defenses

Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.

30 May 2012

Secreted vesicles play role in spread of cancer

Cancer researchers have known for well over a century that different tumor types spread only to specific, preferred organs. But no one has been able to determine the mechanisms of organ specific metastasis, the so-called "soil and seed" theory of 1889. New details that could help shed light on this hypothesis have been provided by a team of researchers from Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, proposing a new mechanism controlling cancer metastasis that offers fresh diagnostic and treatment potential.

29 May 2012

Fluxion Biosciences announces launch of Discovery Services business

Fluxion Biosciences, a privately held drug discovery tools and services company, announced today that it is launching a Discovery Services business to support growing demand for assay support on Fluxion's unique cell analysis platforms.

From Fluxion Biosciences 29 May 2012

Oncos Therapeutics commences clinical study with oncolytic viruses

Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors.

29 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

Bioengineers develop first structure to grow small human blood vessels

Mice and monkeys don't develop diseases in the same way that humans do. Nevertheless, after medical researchers have studied human cells in a Petri dish, they have little choice but to move on to study mice and primates. University of Washington bioengineers have developed the first structure to grow small human blood vessels, creating a 3-D test bed that offers a better way to study disease, test drugs and perhaps someday grow human tissues for transplant.

29 May 2012

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

28 May 2012